GLP-1 in pregnancy

GLP-1 medications are not meant to be taken during pregnancy, and the labels say so plainly. The Wegovy label instructs patients taking it for weight reduction to stop when a pregnancy is recognized, and the Zepbound and Saxenda labels carry the same instruction. The reasoning is twofold: animal reproduction studies signal possible harm to the fetus, and deliberate weight loss offers no benefit to a pregnant patient.

The number most people need is the washout. Wegovy’s label tells patients on the weight-reduction or cardiovascular indication to stop at least 2 months before a planned pregnancy, specifically because semaglutide has a long half-life and lingers in the body. Two months is not a safety margin someone invented — it is the labeled instruction. Our washout explainer walks through how that timeline interacts with a titration schedule you may not want to restart from zero.

There is a birth-control wrinkle that surprises people. Because tirzepatide slows stomach emptying, the Zepbound label advises patients using oral contraceptives to switch to a non-oral method, or add a barrier method, for a defined window after starting the drug and after each dose increase. In other words, starting a GLP-1 can temporarily make the pill less reliable at the exact moment you least want a surprise.

If a pregnancy happens while you are on the medication, an exposure registry exists to collect outcomes. Novo Nordisk runs one for Wegovy and encourages patients and clinicians to enroll by phone or through the registry website. Signing up does not change your care; it adds a data point to the very thin human evidence base that future patients will rely on.

Worth asking your clinician: whether your specific drug’s washout differs, what to do if a pregnancy is unplanned and already underway, how to manage blood-sugar control during the gap if you also have diabetes, and what the plan is for restarting afterward. Our pregnancy and fertility cheat sheet is a useful thing to bring to that appointment.